Ravi B Patel1, Sanjiv J Shah1, Gregg C Fonarow2, Javed Butler3, Muthiah Vaduganathan4. 1. Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 2. Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles, Los Angeles, CA, USA. 3. Division of Cardiology, Stony Brook University, Stony Brook, NY, USA. 4. Brigham and Women's Heart & Vascular Center and Harvard Medical School, 75 Francis St, Boston, MA, USA. mvaduganathan@partners.org.
Abstract
PURPOSE OF REVIEW: Spironolactone did not demonstrate benefit with respect to the primary composite endpoint in the global TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) trial in patients with chronic heart failure with preserved ejection fraction (HFpEF). We identify key lessons from the TOPCAT experience that can be applied to future HFpEF trials. RECENT FINDINGS: Subsequent analyses of TOPCAT have revealed marked regional heterogeneity in patient profiles, event rates, drug adherence, and treatment effects. Significant regional variation may impact the success of global HFpEF trials. Given potential benefits in the Americas subgroup in TOPCAT, mineralocorticoid receptor antagonists can be considered in appropriately selected patients with HFpEF to reduce risk of heart failure hospitalization. A planned registry-based trial should provide additional evidence regarding the role of spironolactone in HFpEF. The overall design, execution, and study oversight of TOPCAT have provided key insights into the conduct of future HFpEF trials.
PURPOSE OF REVIEW: Spironolactone did not demonstrate benefit with respect to the primary composite endpoint in the global TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) trial in patients with chronic heart failure with preserved ejection fraction (HFpEF). We identify key lessons from the TOPCAT experience that can be applied to future HFpEF trials. RECENT FINDINGS: Subsequent analyses of TOPCAT have revealed marked regional heterogeneity in patient profiles, event rates, drug adherence, and treatment effects. Significant regional variation may impact the success of global HFpEF trials. Given potential benefits in the Americas subgroup in TOPCAT, mineralocorticoid receptor antagonists can be considered in appropriately selected patients with HFpEF to reduce risk of heart failure hospitalization. A planned registry-based trial should provide additional evidence regarding the role of spironolactone in HFpEF. The overall design, execution, and study oversight of TOPCAT have provided key insights into the conduct of future HFpEF trials.
Entities:
Keywords:
Clinical trials; Heart failure with preserved ejection fraction; International variation; Mineralocorticoid receptor antagonists; Spironolactone; Study design
Authors: Darren B Taichman; Joyce Backus; Christopher Baethge; Howard Bauchner; Peter W de Leeuw; Jeffrey M Drazen; John Fletcher; Frank A Frizelle; Trish Groves; Abraham Haileamlak; Astrid James; Christine Laine; Larry Peiperl; Anja Pinborg; Peush Sahni; Sinan Wu Journal: N Engl J Med Date: 2016-01-20 Impact factor: 91.245
Authors: Matthew E Harinstein; Javed Butler; Stephen J Greene; Gregg C Fonarow; Norman L Stockbridge; Christopher M O'Connor; Marc A Pfeffer; Mandeep R Mehra; Scott D Solomon; Clyde W Yancy; Mona Fiuzat; Robert J Mentz; Sean P Collins; John J V McMurray; Muthiah Vaduganathan; Preston M Dunnmon; Giuseppe M C Rosano; Wilfried Dinh; Frank Misselwitz; Robert O Bonow; Mihai Gheorghiade Journal: Heart Fail Rev Date: 2015-07 Impact factor: 4.214
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake Journal: J Am Coll Cardiol Date: 2017-04-28 Impact factor: 24.094
Authors: Simon de Denus; Eileen O'Meara; Akshay S Desai; Brian Claggett; Eldrin F Lewis; Grégoire Leclair; Martin Jutras; Joël Lavoie; Scott D Solomon; Bertram Pitt; Marc A Pfeffer; Jean L Rouleau Journal: N Engl J Med Date: 2017-04-27 Impact factor: 91.245
Authors: Marc A Pfeffer; Brian Claggett; Susan F Assmann; Robin Boineau; Inder S Anand; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; John F Heitner; Eldrin F Lewis; Eileen O'Meara; Jean-Lucien Rouleau; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Sonja M McKinlay; Bertram Pitt Journal: Circulation Date: 2014-11-18 Impact factor: 29.690
Authors: Venkatesh Y Anjan; Timothy M Loftus; Michael A Burke; Nausheen Akhter; Gregg C Fonarow; Mihai Gheorghiade; Sanjiv J Shah Journal: Am J Cardiol Date: 2012-06-07 Impact factor: 2.778
Authors: Inder S Anand; Brian Claggett; Jiankang Liu; Amil M Shah; Thomas S Rector; Sanjiv J Shah; Akshay S Desai; Eileen O'Meara; Jerome L Fleg; Marc A Pfeffer; Bertram Pitt; Scott D Solomon Journal: JACC Heart Fail Date: 2017-04 Impact factor: 12.035
Authors: Saul Blecker; Stuart D Katz; Leora I Horwitz; Gilad Kuperman; Hannah Park; Alex Gold; David Sontag Journal: JAMA Cardiol Date: 2016-12-01 Impact factor: 14.676
Authors: James R Sowers; Javad Habibi; Guanghong Jia; Brian Bostick; Camila Manrique-Acevedo; Guido Lastra; Yan Yang; Dongqing Chen; Zhe Sun; Timothy L Domeier; William Durante; Adam T Whaley-Connell; Michael A Hill; Frederic Jaisser; Vincent G DeMarco; Annayya R Aroor Journal: Metabolism Date: 2020-04-07 Impact factor: 8.694
Authors: Lydia E Matesic; Lisa A Freeburg; Laura B Snyder; Lauren-Ashley Duncan; Amber Moore; Paige E Perreault; Kia N Zellars; Edie C Goldsmith; Francis G Spinale Journal: Am J Physiol Heart Circ Physiol Date: 2020-08-21 Impact factor: 4.733